Overview Liraglutide for Low-responders After Bariatric Surgery Status: Withdrawn Trial end date: 2021-12-31 Target enrollment: Participant gender: Summary To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery. Phase: N/A Details Lead Sponsor: Zuyderland Medisch CentrumCollaborator: Nederlandse Obesitas KliniekTreatments: Liraglutide